Collaborating authors are listed in Appendix 1. Other members of the PTC124-GD-007-DMD Study Group are listed in Appendix 2 in the Supporting Information.
The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study
Version of Record online: 17 JUL 2013
Copyright © 2013 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 48, Issue 3, pages 357–368, September 2013
How to Cite
McDonald, C. M., Henricson, E. K., Abresch, R. T., Florence, J., Eagle, M., Gappmaier, E., Glanzman, A. M., PTC124-GD-007-DMD Study Group, Spiegel, R., Barth, J., Elfring, G., Reha, A. and Peltz, S. W. (2013), The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve, 48: 357–368. doi: 10.1002/mus.23905
The study was sponsored by PTC Therapeutics, Inc. (South Plainfield, New Jersey, USA), which was responsible for all aspects of the study, and by a grant from the FDA Office of Orphan Products.
Disclosures: C.M.M is a member of the Cooperative Neuromuscular Research Group (CINRG) Executive Committee and has served on advisory committees for PTC Therapeutics, Inc., Sarepta Therapeutics, Inc., GlaxoSmithKline, Prosensa, Halo Therapeutics, Shire HGT, Cardero Therapeutics, and Novartis AG. E.K.H. is a member of the CINRG Executive Committee and has served as a consultant for Genzyme Corporation and PTC Therapeutics, Inc. R.T.A. has served as a consultant for PTC Therapeutics, Inc., and Sarepta Therapeutics. J.M.F. serves on a scientific advisory board for Prosensa, on the editorial board of Neuromuscular Disorders, and serves/has served as a member of the CINRG Executive Committee and as a consultant for Prosensa, GlaxoSmithKline, Genzyme Corporation, PTC Therapeutics, Inc., and Acceleron Pharma. M.E. has served as a clinical evaluator trainer for PTC Therapeutics, and as a consultant for Prosensa and GlaxoSmithKline. E.G. has served as a clinical evaluator trainer for PTC Therapeutics. A.M.G. has served as a clinical evaluator trainer for PTC Therapeutics. R.S. is the Chief Medical Officer for PTC Therapeutics. J.B. is the Vice President for Clinical Development at PTC Therapeutics. G.E. is the Executive Director of Biostatistics at PTC Therapeutics. A.R. is the Director of Clinical Development at PTC Therapeutics. S.W.P. is the Chief Executive Officer and founding scientist, PTC Therapeutics, Inc.
- Issue online: 27 AUG 2013
- Version of Record online: 17 JUL 2013
- Accepted manuscript online: 14 MAY 2013 10:04AM EST
- Manuscript Accepted: 7 MAY 2013
Additional Supporting Information may be found in the online version of this article.
|mus23905-sup-0001-SuppInfo.doc||94K||Supporting Information Appendix 1|
|mus23905-sup-0002-SuppInfo.docx||15K||Supporting Information Appendix 2|
|mus23905-sup-0003-SuppInfo.docx||18K||Supporting Information Appendix 3|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.